Gene Therapy - Table of Contents alert Volume 19 Issue 2

Special Issue: Gene Therapy for Eye Diseases Guest Editor Robin R Ali, University College London, United Kingdom Over the last decade it has become increasingly clear that eye disorders are amongst the most amenable targets for gene therapy. This issue surveys ocular gene transfer using AAV and lentiviral vectors which are the most effective vector platforms for the eye and also surveys gene therapy approaches for the treatment of a range of retinal disorders, including inherited retinopathies, glaucoma and retinal and choroidal neovascularisation. TABLE OF CONTENTS Volume 19, Issue 2 (February 2012) In this issue Editorial Reviews Short Communications Enabling Technologies Original Articles Erratum Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Access IBMS BoneKEy The premier online knowledge environment for bone health. As a registered user of Nature Publishing Group, you now have access to IBMS BoneKEy. This new platform features webinars, commentaries, BoneKEy Community, BoneKEy Genetics Portal, BoneKEy Reports and much more.   Editorial Top Ocular gene therapy: introduction to the special issue R R Ali Gene Ther 2012 19: 119-120; 10.1038/gt.2011.189 Full Text | PDF Reviews Top Gene transfer for ocular neovascularization and macular edema P A Campochiaro Gene Ther 2012 19: 121-126; advance online publication, November 10, 2011; 10.1038/gt.2011.164 Abstract | Full Text Gene therapy for retinal ganglion cell neuroprotection in glaucoma A M Wilson and A Di Polo Gene Ther 2012 19: 127-136; advance online publication, October 6, 2011; 10.1038/gt.2011.142 Abstract | Full Text Gene-based therapies for dominantly inherited retinopathies G J Farrar, S Millington-Ward, N Chadderton, P Humphries and P F Kenna Gene Ther 2012 19: 137-144; advance online publication, November 17, 2011; 10.1038/gt.2011.172 Abstract | Full Text Ocular gene delivery using lentiviral vectors K S Balaggan and R R Ali Gene Ther 2012 19: 145-153; advance online publication, November 3, 2011; 10.1038/gt.2011.153 Abstract | Full Text Gene supplementation therapy for recessive forms of inherited retinal dystrophies A J Smith, J W B Bainbridge and R R Ali Gene Ther 2012 19: 154-161; advance online publication, October 27, 2011; 10.1038/gt.2011.161 Abstract | Full Text Novel adeno-associated viral vectors for retinal gene therapy L H Vandenberghe and A Auricchio Gene Ther 2012 19: 162-168; advance online publication, October 13, 2011; 10.1038/gt.2011.151 Abstract | Full Text Optogenetic therapy for retinitis pigmentosa V Busskamp, S Picaud, J A Sahel and B Roska Gene Ther 2012 19: 169-175; advance online publication, October 13, 2011; 10.1038/gt.2011.155 Abstract | Full Text Short Communications Top Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9 D Dalkara, L C Byrne, T Lee, N V Hoffmann, D V Schaffer and J G Flannery Gene Ther 2012 19: 176-181; advance online publication, October 20, 2011; 10.1038/gt.2011.163 Abstract | Full Text Absence of ocular malignant transformation after sub-retinal delivery of rAAV2/2 or integrating lentiviral vectors in p53-deficient mice K S Balaggan, Y Duran, A Georgiadis, C Thaung, S E Barker, P K Buch, A MacNeil, S Robbie, J W B Bainbridge, A J Smith and R R Ali Gene Ther 2012 19: 182-188; advance online publication, November 24, 2011; 10.1038/gt.2011.194 Abstract | Full Text Enabling Technologies Top Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors Y Zhao, D H Lam, J Yang, J Lin, C K Tham, W H Ng and S Wang Gene Ther 2012 19: 189-200; advance online publication, June 2, 2011; 10.1038/gt.2011.82 Abstract | Full Text Original Articles Top Jaagsiekte sheep retrovirus pseudotyped lentiviral vector-mediated gene transfer to fetal ovine lung M G Davey, P W Zoltick, C A Todorow, M P Limberis, E D Ruchelli, H L Hedrick and A W Flake Gene Ther 2012 19: 201-209; advance online publication, June 9, 2011; 10.1038/gt.2011.83 Abstract | Full Text Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis S Uhrig, O Coutelle, T Wiehe, L Perabo, M Hallek and H Büning Gene Ther 2012 19: 210-218; advance online publication, June 9, 2011; 10.1038/gt.2011.78 Abstract | Full Text Regulation of gene expression in prostate cancer cells with an artificially constructed promoter responsive to radiation A Morii, R Ogawa, A Watanabe, S Kakutani, Q L Zhao, K Kume, T Kondo and H Fuse Gene Ther 2012 19: 219-227; advance online publication, June 23, 2011; 10.1038/gt.2011.89 Abstract | Full Text Experimental autoimmune hearing loss is exacerbated in IL-10-deficient mice and reversed by IL-10 gene transfer B Zhou, M H Kermany, Q Cai, C Cai, Y Zhou, U Nair, W Liu and T J Yoo Gene Ther 2012 19: 228-235; advance online publication, June 23, 2011; 10.1038/gt.2011.88 Abstract | Full Text Erratum Top Novel adeno-associated viral vectors for retinal gene therapy L H Vandenberghe and A Auricchio Gene Ther 2012 19: 236; advance online publication, November 24, 2011; 10.1038/gt.2011.199 Full Text Advertisement Cell Signaling, Disease and Stem Cells Special Issue and Web Focus The January special issue of Cell Research and the accompanying web focus in the field of Cell Signaling, Disease and Ste Cells present recent advances in various aspects of cell signalling and stem cell biology, and their relevance to disease pathogenesis. Access the Cell Signaling, Disease and Stem Cells Web Focus today!   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Gene Therapy. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.